A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy

Sexual Health

Volumn 3, Issue 4, 2006, Pages 287-290

  Carter, V M ^a   Woolley, I ^a   Jolley, D ^b   Nyulasi, I ^a   Mijch, A ^a   Dart, A ^a  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; FISH OIL; NUCLEOSIDE; NUCLEOSIDE ANALOG; OLIVE OIL; OMEGA 3 FATTY ACID; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FAT INTAKE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; MALE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; HIV INFECTIONS; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33751162633     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH06001     Document Type: Article

References (15)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8. doi: 10.1097/00002030-199807000-00003
2. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62. doi: 10.1056/NEJMra041811
3. Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med 2001; 2: 174-80. doi: 10.1046/j.1468-1293. 2001.00073.x
4. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000; 5: 329-33.
5. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-7.
6. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Data collection on adverse events of anti-HIV drugs (DAD) study group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003. doi: 10.1056/NEJMoa030218
7. Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000; 20: 1066-71. doi: 10.1592/phco.20.13.1066.35033
8. Bang HO, Dyerberg J, Hjoorne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand 1976; 200: 69-73.
9. Weber P, Raederstorff D. Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids - a review. Nutr Metab Cardiovasc Dis 2000; 10: 28-37.
10. O'Keefe JH Jr, Harris WS. From Inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc 2000; 75: 607-14.
11. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial. Lancet 1989; 334: 757-61. doi: 10.1016/S0140-6736(89)90828-3
12. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-55. doi: 10.1016/S0140-6736(99)07072-5
13. Lipid management guidelines. Med J Aust 175, Supplement: S57-S90. http://www.heartfoundation.com.au/downloads/Guideline_Lipid_Mgt_2001.pdf [verified October 2006].
14. De Truchis P, Kirstetter M, Perier A, Meunier C, Gardette J, Melchior JC, Maxepa VIH. Study group treatment of hypertriglyceridemia in HIV-infected patients under HAART, by (n-3) polyunsaturated fatty acids: a double-blind randomized prospective trial in 122 patients. In '12th Conference on Retroviruses and Opportunistic Infections, Boston 2005'. [Abstract 39].
15. Wohl DA, Tien HC, Busby M, Cunningham C, Macintosh B, Napravnik S, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 2005; 41: 1498-504. doi: 10.1086/497273